Obstetrical considerations and management of antiphospholipid syndrome

Karen Gibbins, Robert M. Silver

Research output: Contribution to journalArticle

Abstract

Antiphospholipid syndrome is a pro-thrombotic, pro-inflammatory condition defined by at least one clinical criterion and one laboratory finding. Clinical criteria are met by history of thrombosis or obstetric morbidity, including recurrent early pregnancy loss, fetal death, or delivery prior to 34 weeks gestation due to pre-eclampsia or placental insufficiency. Laboratory criteria are evidence of lupus anticoagulant or high titers of anticardiolipin or anti-ß2- glycoprotein-I IgG or IgM. Treatment during pregnancy is primarily based on anticoagulant therapy, either at prophylactic or therapeutic doses depending on thrombosis history. This treatment certainly reduces thrombosis risk and may also improve obstetric outcome.

Original languageEnglish (US)
Pages (from-to)22-26
Number of pages5
JournalOpen Urology and Nephrology Journal
Volume8
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Antiphospholipid Syndrome
Thrombosis
Pregnancy
Obstetrics
Placental Insufficiency
Lupus Coagulation Inhibitor
Fetal Death
Pre-Eclampsia
Anticoagulants
Immunoglobulin M
Glycoproteins
Immunoglobulin G
Morbidity
Therapeutics

Keywords

  • Antiphospholipid syndrome
  • Pre-eclampsia
  • Pregnancy loss
  • Stillbirth

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Obstetrical considerations and management of antiphospholipid syndrome. / Gibbins, Karen; Silver, Robert M.

In: Open Urology and Nephrology Journal, Vol. 8, 01.01.2015, p. 22-26.

Research output: Contribution to journalArticle

@article{e663a330857544389adefb4c1956ee21,
title = "Obstetrical considerations and management of antiphospholipid syndrome",
abstract = "Antiphospholipid syndrome is a pro-thrombotic, pro-inflammatory condition defined by at least one clinical criterion and one laboratory finding. Clinical criteria are met by history of thrombosis or obstetric morbidity, including recurrent early pregnancy loss, fetal death, or delivery prior to 34 weeks gestation due to pre-eclampsia or placental insufficiency. Laboratory criteria are evidence of lupus anticoagulant or high titers of anticardiolipin or anti-{\ss}2- glycoprotein-I IgG or IgM. Treatment during pregnancy is primarily based on anticoagulant therapy, either at prophylactic or therapeutic doses depending on thrombosis history. This treatment certainly reduces thrombosis risk and may also improve obstetric outcome.",
keywords = "Antiphospholipid syndrome, Pre-eclampsia, Pregnancy loss, Stillbirth",
author = "Karen Gibbins and Silver, {Robert M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2174/1874303X01508010022",
language = "English (US)",
volume = "8",
pages = "22--26",
journal = "Open Urology and Nephrology Journal",
issn = "1874-303X",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Obstetrical considerations and management of antiphospholipid syndrome

AU - Gibbins, Karen

AU - Silver, Robert M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Antiphospholipid syndrome is a pro-thrombotic, pro-inflammatory condition defined by at least one clinical criterion and one laboratory finding. Clinical criteria are met by history of thrombosis or obstetric morbidity, including recurrent early pregnancy loss, fetal death, or delivery prior to 34 weeks gestation due to pre-eclampsia or placental insufficiency. Laboratory criteria are evidence of lupus anticoagulant or high titers of anticardiolipin or anti-ß2- glycoprotein-I IgG or IgM. Treatment during pregnancy is primarily based on anticoagulant therapy, either at prophylactic or therapeutic doses depending on thrombosis history. This treatment certainly reduces thrombosis risk and may also improve obstetric outcome.

AB - Antiphospholipid syndrome is a pro-thrombotic, pro-inflammatory condition defined by at least one clinical criterion and one laboratory finding. Clinical criteria are met by history of thrombosis or obstetric morbidity, including recurrent early pregnancy loss, fetal death, or delivery prior to 34 weeks gestation due to pre-eclampsia or placental insufficiency. Laboratory criteria are evidence of lupus anticoagulant or high titers of anticardiolipin or anti-ß2- glycoprotein-I IgG or IgM. Treatment during pregnancy is primarily based on anticoagulant therapy, either at prophylactic or therapeutic doses depending on thrombosis history. This treatment certainly reduces thrombosis risk and may also improve obstetric outcome.

KW - Antiphospholipid syndrome

KW - Pre-eclampsia

KW - Pregnancy loss

KW - Stillbirth

UR - http://www.scopus.com/inward/record.url?scp=84930679910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930679910&partnerID=8YFLogxK

U2 - 10.2174/1874303X01508010022

DO - 10.2174/1874303X01508010022

M3 - Article

VL - 8

SP - 22

EP - 26

JO - Open Urology and Nephrology Journal

JF - Open Urology and Nephrology Journal

SN - 1874-303X

ER -